Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVX000222 in Stable Coronary Artery Disease
NCT01058018Phase 2Completed
- Sponsor
- Resverlogix Corp.
- Start
- Dec 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apabetalone in coronary artery disease (CAD), atherosclerosis, sponsored by Resverlogix Corp.. Started Dec 2009; status: completed.
02
Drugs
apabetalone
03
Conditions
coronary artery disease (CAD)atherosclerosis
Beyond the preview
Go deeper on NCT01058018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01058018.